US14070B3096
© Globe Newswire
16.12.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
News Preview
– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET –...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
News Preview
SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $25.00 per share. Capricor also granted th...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
News Preview
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel, the Company’s investigational cell therap...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
03.11.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
News Preview
–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– ...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
31.10.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
News Preview
Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting
News Preview
SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced a regulatory update for its Biologics License Application (BLA) for Deramiocel, the Company’s investigational cell therapy for the treatment of...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
CAPR
LISTED
NASDAQ
FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) and reminds investors of the September 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
CAPR
LISTED
NASDAQ
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR).
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of mill...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
News Preview
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today issued a statement regarding the U.S. Food and Drug Administration’s (FDA) public posting of its Complete Response Letter (CRL) for the Biologics License...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
CAPR
LISTED
NASDAQ
CAPR INVESTOR ALERT: Kirby McInerney LLP Notifies Capricor Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
News Preview
Kirby McInerney LLP reminds Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) investors of the September 15, 2025 deadline to seek the role of lead plaintiff in a pending federal securities class action.
If you purchased or otherwise acquired Capricor securities, have information, or would like to learn more, please contac...
Themefolio
Profiler
Peergroup
© BusinessWire
06.09.2025
CAPR
LISTED
NASDAQ
CAPR Deadline: Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company.
For more information, submit a form, email attorney...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2025
CAPR
LISTED
NASDAQ
CAPR INVESTORS: Kirby McInerney LLP Reminds Capricor Therapeutics, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm
News Preview
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) securities during the period of October 9, 2024 through July 10, 2025 inclusive (“the Class Period”).
If you suffered a loss on your Capricor investm...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
18.08.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
News Preview
SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the first subjects have been dosed in a Phase 1 clinical trial evaluating its StealthX™ exosome-based vaccine. The study, funded by the Nat...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.08.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News Preview
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced its financial results for the second quarter ended June 30, 2025, and provided a corporate update....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
News Preview
– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET – – Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –...
Themefolio
Profiler
Peergroup
© BusinessWire
22.07.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
News Preview
The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR d...
Themefolio
Profiler
Peergroup
© BusinessWire
21.07.2025
CAPR
LISTED
NASDAQ
Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”). Capricor is a clinical-stage biotechnology company.
For m...
Themefolio
Profiler
Peergroup
© BusinessWire
21.07.2025
CAPR
LISTED
NASDAQ
Gibbs Mura Announces a Securities Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR); CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura
News Preview
Gibbs Mura announces that a class action lawsuit was filed against Capricor Therapeutics, Inc. on behalf of investors who purchased or acquired Capricor securities between October 9, 2024 and July 10, 2025. Shares of Capricor plunged over 30% in intraday trading on Friday, July 11, 2025, after the U.S. Food and Drug Administration rejected the com...
Themefolio
Profiler
Peergroup
© BusinessWire
18.07.2025
CAPR
LISTED
NASDAQ
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commiss...
Themefolio
Profiler
Peergroup
© BusinessWire
11.07.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura
News Preview
Shares of Capricor Therapeutics, Inc. plunged over 30% in intraday trading on Friday, July 11, 2025, after the U.S. Food and Drug Administration rejected the company’s Biologics License Application for its lead cell therapy candidate, Deramiocel, claiming that the application “does not meet the statutory requirement for substantial evidence of eff...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
News Preview
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Applicati...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
News Preview
SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell t...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
News Preview
SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the successful completion of the U.S. Food and Drug Administration’s (FDA) Pre-License Inspection (PLI) of its San Diego manufa...
Themefolio
Profiler
Peergroup
© BusinessWire
17.05.2025
CAPR
LISTED
NASDAQ
CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (NASDAQ: CAPR) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or fa...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
News Preview
Company to Host Conference Call, May 13, 2025 at 4:30 p.m. ET Company to Host Conference Call, May 13, 2025 at 4:30 p.m. ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.03.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
News Preview
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a corporate update....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.03.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
News Preview
--Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data Presented at the 2025 Muscular Dystrophy Association (MDA) Conference--...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.03.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
News Preview
Company to Host Conference Call, March 19, 2025 at 4:30 p.m. ET Company to Host Conference Call, March 19, 2025 at 4:30 p.m. ET...
Themefolio
Profiler
Peergroup
© PR Newswire
10.03.2025
CAPR
LISTED
NASDAQ
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
News Preview
PARAMUS, N.J., March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that acceptance has been received by Capricor Therapeutics, Inc. (Headquarters: California, USA, CEO: Linda Marbán, NASDAQ: CAPR) from the U.S. Food and Drug Administration (FDA) for the Biologics...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.03.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
News Preview
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that Capricor management will participate in one-on-one investor meetings and provide a corporate update at Leerink’s Global H...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.01.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
News Preview
-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy-...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2024
CAPR
LISTED
NASDAQ
Capricor Therapeutics to Present at Upcoming Investor Conferences
News Preview
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at the following upcoming investor conferences....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2024
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
News Preview
SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today the closing of its previously announced underwritten public offering of 5,073,800 shares of its common stock, including the exe...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2024
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
News Preview
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to gra...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.10.2024
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
News Preview
-Data Supports Deramiocel’s Sustained Efficacy and Safety in Treating DMD-...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2024
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
News Preview
-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA-...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.10.2024
CAPR
LISTED
NASDAQ
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
News Preview
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today that the Company will present the three-year safety and efficacy results from its HOPE-2 open-label extension (OLE) study with...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2024
CAPR
LISTED
NASDAQ
Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
News Preview
Investor Webcast on Tuesday, September 24, 2024 at 8:30 a.m. ET Investor Webcast on Tuesday, September 24, 2024 at 8:30 a.m. ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2024
CAPR
LISTED
NASDAQ
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
News Preview
-Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Million in Potential Milestones and a Double-Digit Percentage of Product Revenue-...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.09.2024
CAPR
LISTED
NASDAQ
Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
News Preview
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming investor and scientific conferences....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.06.2024
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
News Preview
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients-...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
CAPR
LISTED
NASDAQ
CORRECTION: Capricor Therapeutics
News Preview
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted from the headline. The corrected release follows....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2024
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
News Preview
--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the succ...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2024
CAPR
LISTED
NASDAQ
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
News Preview
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024–...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2024
CAPR
LISTED
NASDAQ
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
News Preview
-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)-...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
